Endocrine Abstracts

Purpose: Although the majority of differentiated thyroid cancer (DTC) patients have favorable outcome, approximately up to 20% of them may develop metastatic and/or locoregional disease persistence. One-third of those patients may not respond to the treatment with radioiodine (RAI refractory DTC, RAI-R DTC). There are few reports of real-life experience concerning the clinical course and the treatment modalities that have been used in patients with RAI-R DTC.<p class="abst...